ZEN003694
Phase 2Small molecule
ZEN003694 is one of 89 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
4
Indications
8
Total Trials
4
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
312 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Leuprorelin
TakedaPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Acetylsalicylic Acid
BayerPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
ZEN003694
ZZenith Epigenetics
Phase 2
Rhpsma-7.3 (18f)
BBlue Earth Diagnostics
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Solid Tumors1 trial
Ovarian Cancer1 trial
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Recruiting·—·Phase 2·NCT05071937·33 enrolled
Breast Cancer1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZEN003694. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZenith Epigenetics